Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Ascenta Therapeutics

3

Pfizer

420

Eli Lilly

239

Merck

238

GlaxoSmithKline

197

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Baculoviral IAP repeat-containing protein 2

3

Baculoviral IAP repeat-containing protein 3

3

Inhibitor of apoptosis protein 3

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Acute myelogenous leukemia

3

Head and neck squamous cell carcinoma

3

Lymphoma

3

Ovarian cancer

3

Solid tumors

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

FDA UNII

3

PUBCHEM

3

EPA CompTox

1

EU-Orphan Drug

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

Xevinapant

N65WC8PXDD

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Baculoviral IAP repeat-containing protein 2

Baculoviral IAP repeat-containing protein 3

Inhibitor of apoptosis protein 3

Conditions:

Head and neck squamous cell carcinoma

Acute myelogenous leukemia

AT-406 (DEBIO-1143, SM-406), is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406 inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in ...

mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Debiopharm under a licence from Ascenta Therapeutics is developing AT-406 for the treatment of cancers.

SM-433

DH7Q8HYP47

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Baculoviral IAP repeat-containing protein 2

Baculoviral IAP repeat-containing protein 3

Inhibitor of apoptosis protein 3

Conditions:

Head and neck squamous cell carcinoma

Acute myelogenous leukemia

AT-406 (DEBIO-1143, SM-406), is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406 inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in ...

mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Debiopharm under a licence from Ascenta Therapeutics is developing AT-406 for the treatment of cancers.

XEVINAPANT HYDROCHLORIDE

73T1W2MF9C

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Baculoviral IAP repeat-containing protein 2

Baculoviral IAP repeat-containing protein 3

Inhibitor of apoptosis protein 3

Conditions:

Head and neck squamous cell carcinoma

Acute myelogenous leukemia

AT-406 (DEBIO-1143, SM-406), is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406 inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in ...

mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Debiopharm under a licence from Ascenta Therapeutics is developing AT-406 for the treatment of cancers.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1